Agios Pharmaceuticals (AGIO)VA awarded $73K

$73K

committed so far

Signed

Jul 14, 2026

Updated

Jul 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 18, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. (the “Company”) held on June 18, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2023 Plan Amendment”) to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan (the “Current Plan”).”
2. Jul 14, 2026 · this disclosureFederal contract · $73K obligatedDepartment of Veterans Affairs awarded AGIOS PHARMACEUTICALS, INC.: $73K obligated to date

What came next

1. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 20, 2026CongressDisclosed purchase of AGIO — reported range $1,001 - $15,000

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Agios Pharmaceuticals

For Agios Pharmaceuticals, OQRO holds 1 Congress trade report, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AGIO page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Agios Pharmaceuticals

• House Clerk periodic transaction reportSep 10, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRJul 28, 2026

Everything OQRO holds on this company is on its AGIO page.